MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Investment Ideas Pro

What Does the Angelini Pharma Acquisition Mean for Catalyst Pharmaceuticals (CPRX) Shareholders

9 hours ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Does Hapag-Lloyd's Acquisition Mean for ZIM Shareholders

3 months ago

What Does YUVIWEL's FDA Approval Mean for Ascendis Pharma

2 months ago

What Does the Recent Thalassemia Approval Mean for Agios Pharmaceuticals

3 weeks ago

What Does FCPT's Latest Acquisition Mean for Its Portfolio

4 days ago

These Are The Upcoming Catalysts For Crispr Therapeutics Stock

CRSP shares face a long-term growth outlook driven by a diversified clinical pipeline and a strategic partnership with Vertex. While Casgevy adoption remains slow due to preconditioning hurdles, upcom...

CRSP

Stock News•1 week ago

CPRX or UTHR: Which Is the Better Value Stock Right Now?

Investors are evaluating Catalyst Pharmaceuticals (CPRX) and United Therapeutics (UTHR) to determine which drug manufacturer offers superior value. The comparison focuses on current market positioning...

CPRX

Stock News•2 weeks ago

Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Catalyst Pharmaceuticals (CPRX) faces investor scrutiny ahead of its Q1 2026 earnings report. Analysts are shifting focus beyond headline revenue and EPS figures to evaluate specific key performance m...

CPRX

Stock News•2 weeks ago

CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Catalyst Pharmaceuticals (CPRX) is under investigation by Halper Sadeh LLC regarding its proposed $31.50 per share cash sale to Angelini Pharma S.p.A. The firm is evaluating whether the board secured ...

CPRX